
Belgian biotech firm Precirix has finished a series B financing round raising EUR 80m, a press release reports.
The round was led by new investors Inkef Capital, Jeito and Forbion, which join the company’s ownership circle that already counts Novo Holdings, Gimv, Healthcap, Pontifax Venture Capital, V-Bio Ventures and Biomed Partners. The existing owners participated in the fundraising round alongside the company’s seed investors.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app